USFDA inspects Alembic Pharma's solid oral formulation facility at Jarod

Alembic Pharmaceuticals announced that the United States Food and Drug Administration (USFDA) has conducted PAI (Pre-Approval Inspection) at Alembic Pharmaceuticals' Solid Oral Formulation Facility (F-4) located at Jarod. The USFDA issued a Form 483 with 5 procedural observations.

None of the observations are related to data integrity and management believes that they are addressable.

Powered by Capital Market - Live News